The Proportional Venn Diagram of Obstructive Lung Disease. Part 6
In the subpopulation of participants aged > 50 years, the prevalence of current asthma was 5.1%, the prevalence of current chronic bronchitis was 5.8%, and the prevalence of ever having had emphysema was 5.0% in the US NHANES III survey. In the UK GPRD subpopulation of participants aged > 50 years, the prevalence of current asthma was 1.6%, the prevalence of current chronic bronchitis was 1.1%, and the prevalence of current emphysema was 1.1% (data not shown). The seven mutually exclusive disease groups of this proportional Venn diagram also can be displayed as stacked bars, for comparison by gender and age (Fig 3). The relative size of the asthma-only group decreased with increasing age, both in women and men in the United States and the United Kingdom. In the NHANES III data, probably because acute bronchitis could have been misclassified as chronic bronchitis in some cases via the self-reported questionnaire, combinations of chronic bronchitis with asthma or chronic bronchitis alone appeared at very young ages. Emphysema was reported consistently from age 50 years onward. Combinations of two of the three OLD conditions occurred among 21.2%, 31.4%, and 14.4%, in those patients in the age groups of 60 to 69 years, 70 to 79 years, and > 80 years, respectively.
By contrast, in the UK GPRD, emphysema and chronic bronchitis are virtually nonexistent diagnoses before 50 years of age. After age 50 years, the frequent diagnoses of chronic bronchitis and emphysema together as COPD gave little room for chronic bronchitis-only or emphysema-only diagnoses. Therefore, combinations of two of the three OLD conditions occurred among 41.5%, 58.8%, and 65.5% of patients in the age groups of 60 to 69 years, 70 to 79 years, and > 80 years, respectively.
Finally, according to the spirometry data of NHANES III, US OLD participants with chronic bronchitis or emphysema, with or without a concomitant diagnosis of asthma, differed widely regarding the prevalence of airflow obstruction among patients with a diagnosis of emphysema only, with only 37.4% of patients having airflow obstruction confirmed by spirometry. The prevalence of airflow obstruction was significantly higher among participants with combinations of emphysema and chronic bronchitis (57.7%), with emphysema and asthma (51.9%), and with all three OLD diseases concomitantly (52.0%). Among all NHANES III participants with airflow obstruction, accounting for 4.8% of the general population, 58.3% reported no diagnosis of any of the three OLD conditions (Fig 4). The patterns of airflow obstruction prevalence were confirmed when the analysis was restricted to participants aged > 50 years (Fig 5). The prevalence of airflow obstruction in the seven mutually exclusive areas were as follows: asthma only, 26.5%; chronic bronchitis only, 29.6%; emphysema only, 45.5%; asthma plus chronic bronchitis, 55.8%; asthma plus emphysema, 48.7%; chronic bronchitis plus emphysema, 59.7%; and asthma plus chronic bronchitis plus emphysema, 49.0%. Still, 9.3% of the NHANES III population who were > 50 years of age had objective airflow obstruction without any respiratory diagnoses.
The Proportional Venn Diagram of Obstructive Lung Disease. Part 5
Before testing, screening questions were asked to determine medical safety exclusions (ie, those who had undergone chest or abdominal surgery within 3 weeks or had experienced heart problems [myocardial infarction or heart attack, angina or chest pain, and congestive heart failure]) within 6 weeks before attending the MEC. Airflow obstruction was defined as stage 1 according to the following Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines: FEV1, < 80% of predicted (based on gender, age, and height); FEVj/FVC ratio, < 70%.4 As children aged < 7 years did not have spirometry measurements recorded in NHANES III, estimates of airflow obstruction were weighted to the sample of participants aged > 8 years for whom spirometry had been measured.
Statistical Analysis
The prevalence for each condition per gender and age group is presented for the United States and the United Kingdom separately. Values have been extrapolated to the total population in each country using the NHANES III sample weights for the United States and using the Office of National Statistics data for the United Kingdom. Each graphic representation in Figures 2 to 5 was calculated by applying simple proportional euclidean geometry, with the area of the circle representing the exact population size. The areas of intersection of circles represent the percentage of overlap of two or three OLD conditions. Analyses were conducted using a statistical software package (SAS, version 8.0; SAS Institute; Cary, NC).
Results
The descriptive characteristics of NHANES III and GPRD participants with OLD are presented in Table 1. Patients were stratified into seven mutually exclusive disease groups by age and sex for each study population. Patients with asthma, in whom diagnoses had been made with or without other OLD conditions, were younger than COPD patients. The combination of asthma with chronic bronchitis, but not with emphysema, was associated with younger age.
In the US NHANES III total population, the prevalence of current asthma was 5.5%, the prevalence of current chronic bronchitis was 3.2%, and the prevalence of ever having had emphysema was 1.5%. In the UK GPRD total population, the prevalence of current asthma was 2.3%, the prevalence of current chronic bronchitis was 0.5%, and the prevalence of current emphysema was 0.5% (Fig 2). The asthma-only group was the largest group of OLD patients, accounting for 4.3% and 2.2%, respectively, of the United States and United Kingdom general populations; that is, 50.3% and 79.4%, respectively, of all OLD patients. Seventeen percent of OLD patients in the United States had more than one OLD condition, and 2.8% had all three conditions simultaneously. The UK figures were 19.1% and 3.6%, respectively. The areas of intersection among the three OLD conditions differed by data source and country (Fig 2).
The Proportional Venn Diagram of Obstructive Lung Disease. Part 4
Such patients often are referred to in the United States as having asthmatic bronchitis or the asthmatic form of COPD. Persons with chronic bronchitis and/or emphysema without airflow obstruction (ie, subsets 1, 2, and 11) are not classified as having COPD. Patients with airway obstruction due to diseases with known etiology or specific pathology, such as cystic fibrosis or obliterative bronchiolitis (subset 10), are not included in this definition. Reprinted with permission from the American Thoracic Society. of a hospital or other specialist visit (ie, inpatient, outpatient, or in an accident and emergency unit) must be recorded when the GP is informed. The diagnosis, symptoms, procedure or investigation, referrals, and their outcome must be entered into the relevant sections of the medical record. In this report, estimates are presented for patients who attended their GP, were given a diagnosis of asthma or COPD, and were registered throughout 1998. Pulmonary function data are not systematically or routinely available.
Case Definitions
Definitions of OLD in each database differ. NHANES III was a survey, and the questionnaire part of the survey asked participants about self-reported physician-diagnosis of three conditions (ie, asthma, chronic bronchitis, and emphysema). A positive response to the single question “Has a doctor ever told you that you have emphysema?” was sufficient to define emphysema. But, for asthma and chronic bronchitis, positive responses to the following two questions were necessary to define a current condition: “Has the doctor ever told you that you have [asthma or chronic bronchitis]?” and ”Do you still have it?“ A participant could be classified as having ah three conditions.
The GPRD system uses the Oxford Medical Information System (OXMIS) and READ coding system (the first three digits of the OXMIS number corresponds, in most cases, to the first three digits of the International Classification of Diseases, eighth revision, codes). Physician-diagnosed asthma, chronic bronchitis, and emphysema were defined as any individual who was labeled with one or more of the OXMIS/READ codes that were compatible with their respective diagnoses during calendar year 1998. This permitted the use of terms like COPD without reference to chronic bronchitis or emphysema. Acute bronchitis was excluded from the algorithm. The choice of GPRD OXMIS/ READ codes was recorded by each individual GP without instructions or guidelines. Direct codes for COPD were defined as overlapping chronic bronchitis and emphysema in the Venn diagrams.
Spirometry in NHANES III
Lung function testing was conducted on participants aged > 8 years by a trained technician in a mobile examination center (MEC). Testing also was conducted at the home of participants aged > 60 years who were unwilling or unable to come to the MEC.
Top Ten List in Ventilator-Associated Pneumonia (Part 5)
This study tested the potential value of routine microbiological cultures before VAP onset in predicting the causative pathogen of VAP and in anticipating the correct antibiotic choice. Authors cultured blood, respiratory secretions, catheter-tips, urine, and others substances, and found that there was no relationship between the colonization of tissues other than from the lungs and the etiology of VAP. High-quality distal bronchial samples obtained by BAL and protected-specimen brush, if cultured in the previous 72 h, had positive predictive values of 25% and 28%, respectively. Only distal respiratory secretions, when repeated at intervals between 48 and 72 h, might have a role in predicting the causative bacteria of VAP. Special attention is required for potentially drug-resistant bacteria like methicillin-resistant Staphylococcus aureus, P aeruginosa, and Acinetobacter baumannii with positive predictive values of 62%, 52%, and 24%, respectively. Previous colonization with any of these pathogens implies a high risk for subsequent pneumonia, allowing for an adequate empiric antibiotic selection.
The authors present the largest study performed in the United States, comprising 842 VAP patients and 2,243 control subjects. The mean interval between intubation and the identification of VAP was 3.3 ± 6.6 days. A crude incidence of 9.3% was found in ventilated patients. The authors also reported morbidity and economic variables resulting in an increase in mean ICU and hospital stays (6.1 days), mean period of mechanical ventilation (9.6 days), and a mean doubled increase in hospital charges ($41,294). P aeruginosa was isolated most frequently in patients with VAP, occurring > 4 days after the start of mechanical ventilation (19.7%), while S aureus was isolated most frequently in patients in whom VAP was diagnosed before the fourth day of onset of mechanical ventilation (23.7%). They found no attributable mortality at 30 days. An outstanding conclusion is that intermediate underlying illness severity is one of the independent risk factors for developing VAP, as reported previously for late-onset VAP episodes caused by P aeruginosa. The main goal of this study concerned the impact on the design of future studies aimed at VAP prevention.
Top Ten List in Ventilator-Associated Pneumonia (Part 4)
This expert group investigated the potential role of nonpathogenic microorganisms in VAP. Three hundred sixty-nine VAP patients were identified during the study period. Only 29 episodes were considered to have been caused by commensal pathogens. The percentage of pathogens of unknown etiology was not reported. Polymicrobial VAP was found in 77 patients, and these patients were excluded from the study. Most patients had risk factors for more virulent or resistant pathogens like COPD, glucocorticoid therapy, or immunosuppression. Although the onset of 10 cases occurred before the sixth ICU day, all Gram-negative commensal pathogens that were isolated were sensitive to therapy with a third-generation cephalosporin or amoxicillin/clavulanic acid. Seven of 29 patients did not receive adequate treatment, and mortality did not increase significantly. Although the authors attribute a pathogenic role to commensal bacteria, they did not find any difference in mortality rate between patients with or without VAP. In addition, besides the limited relevance to mortality, only 20% of patients who died had received histologic confirmation of a diagnosis of pneumonia. Commensal pathogens can produce fulminant infections in immunocompromised patients, but this is the first study that has suggested the need to treat commensal isolates in patients with VAP. Future investigations are needed to define the pathogenic role of commensal agents in these kinds of patients.
The occurrence of and effect on prognosis of delays in the beginning of the treatment of VAP have not been reported before, to our knowledge. Appropriate initial antibiotic treatment has been reported to reduce in-hospital mortality. Iregui et al have found an increase in the hospital mortality rate with delayed initial treatment. Adequate initial treatment usually has been defined as an antibiotic with in vitro susceptibility to the pathogen isolated in respiratory samples. This definition needs the addition of onset timing in antibiotic administration. The most common cause of inadequate initial treatment was a delay in writing the medical orders. The presence of a resistant organism accounted for < 20% of cases. It is important to note that diagnostic delays were not counted, although radiologic criteria included an infiltrate persistence of > 72 h. Inadequate clinical evaluation and waiting for microbiological results were reasons of delayed empiric treatments.
Top Ten List in Ventilator-Associated Pneumonia
Rello J, Lorente C, Bodi M, et al. Why do physicians not follow evidence-based guidelines for preventing ventilator-associated pneumonia?
The article reflects the need to improve medical and nursing staff adherence to guidelines. A total of 110 opinion leaders on VAP from 22 countries were interviewed for their personal opinions on different VAP prevention measures Dapoxetine online. Scientific evidence published alone has been shown to be ineffective in improving guideline implementation because the degree of adherence is independent of the strength of evidence and the grade of effectiveness, at least in part because of the disagreement of opinion leaders about the interpretation of reported trials. However, the most important reason why recommendations are not followed is the lack of technological availability, which has been cited by 78% of the interviewed opinion leaders. Pharmacologic strategies had worse adherence than nonpharmacologic ones, which were predominantly conditioned for excessive antibiotic employment. This report highlighted the great importance of educational measures in improving VAP prevention, remarking on the need for a multidisciplinary approach.
Zack JE, Garrison T, Trovillion E, et al. Effect of an education program aimed at reducing the occurrence of ventilator-associated pneumonia.
This interesting article confirms the huge importance of implementing scientific data with educational programs, and is directed to physicians and nurses in an effort to improve VAP prevention. The reduction in the VAP rate reported is 57.6% (range, 12.6 to 5.7 episodes per 1,000 ventilator days). The program included a theoretical module, with selfstudy and practice modifications, with staff meetings and didactic lectures. The authors reinforced the programs with continuous visual support throughout the ICU, contributing to the adherence to the guidelines. These strategies require constant reinforcement by continuous updating and feedback based on results. It is important to point out that the combination of different measures is an important way to reduce the incidence of VAP. As can be inferred from the study, not only the incidence of VAP can be reduced with educational programs, but also the costs and patient morbidity attributed to nosocomial infections.
http://www.myviagrainaustralia.com/kamagra-oral-jelly.html – Kamagra in Australia online.
Effect of Emphysema on CT Scan Measures of Airway Dimensions in Smokers
COPD is incompletely reversible expiratory airflow obstruction attributed to a combination of emphysema and airway disease. CT imaging is increasingly being used to characterize and quantify these processes for genetic, epidemiologic, and therapeutic investigations with the premise that their relative balance may define unique subsets of disease. Although the quantification of emphysema by CT imaging has been well established and now validated in multiple histopathologic investigations, the quantification of airway disease Canadian Heath&Care Pharmacy has proven to be a greater challenge.
It is believed that the site of expiratory airflow obstruction in COPD is the small airways that are < 2 mm in diameter. Although direct examination of these structures is beyond the resolution of clinical CT scanning techniques, work by Nakano and colleagues demonstrated that dimensions of the central airways and their degree of remodeling on CT scan are correlated with the burden of distal small airways disease. It was subsequently discovered that the correlation between FEV1 % predicted and WA% is greater in subsegmental (and more peripheral) airways than in segmental airways. It has since become the standard in quantitative CT image analyses to study the most peripheral airways.
Previously, we and other groups demonstrated that with increasing disease severity and increasing burdens of emphysema, airways become less distensible. There may be several reasons for this observation, including mural fibrosis, which prevents dilation, and the disruption of the airway parenchymal interdependence in emphysematous lungs, which may reduce radial traction on the airway. In either case, an incompletely expanded airway may appear to have an elevated WA% on CT scan that could be falsely attributed to a greater burden of airway disease. Because the increase in WA% beyond the segmental airways is the basis of the increased correlation between lung function and airway disease, it is important to uncover whether this measure is related to emphysema. Using CT imaging, epidemiologic, and functional data from a large cohort of smokers in the COPDGene Study, we aimed to (1) examine the effect of emphysema on the relationship between WA% and FEV1 % predicted and (2) assess the relationships among lobar emphysema, segmental and subsegmental WA%, and total bronchial area (TBA) along six bronchial paths.
Depression Part 2
What Are the Symptoms of Depression?
- Lack of motivation, or ‘get up and go’. Sometimes even simple tasks can seem difficult.
- Difficulty concentrating, for example, when reading and at work
- Sleep difficulties: difficulty getting to sleep, difficulty staying asleep or early morning wakening. Classically, this early morning wakening occurs when you wake up early but are unable to get back to sleep, and yet you still feel tired. Sometimes people with depression can oversleep.
- Feelings of sadness, sometimes with tearfulness
- Feelings of guilt
- Feelings of hopelessness or worthlessness
- Lack of energy
- Loss of interest in sex
- Erectile dysfunction
- Lack of emotion
- Change in appetite: this is usually a loss of interest in and taste for food with associated weight loss. However, sometimes comfort or binge eating can occur with subsequent weight gain.
- Feelings of irritability, agitation or restlessness
- Mood variation during the day, with symptoms often worse early in the day
- Physical symptoms including headaches, constipation, palpitations, fatigue or feeling tired all the time
- Thoughts of death, which may include passive death wishes, where someone feels they would be better off dead
- A feeling of ‘blackness’
- Occasional suicidal thoughts
As a general rule, the more of the above symptoms you have the more severe the depression. More severe forms of depression, particularly when associated with feelings of hopelessness about the future or worthlessness, can be associated with an increased risk of suicide. Stop Depression with Myviagrainaustralia.com!
Specific Medical Criteria for the Diagnosis of Major Depression
Symptoms of depression must be present nearly every day for at least two weeks and not explained by medical conditions, strokes or recent bereavement.
At least one of these two symptoms should be present:
- Depressed mood
- Severely diminished interest in or pleasure from activities that are usually pleasurable
In addition, at least four of the following seven symptoms should be present:
- Substantial change in appetite or weight loss or, less commonly, weight gain
- Inability to sleep or, less commonly, excessive sleep
- Fatigue or loss of energy
- Diminished physical activity or, less commonly, agitation
- Impaired ability to think, concentrate or make decisions
- Diminished self-esteem, with feelings of worthlessness or inappropriate guilt
- Recurrent thoughts of death or suicide
What Causes Depression?
Depression is thought to occur when there is a chemical imbalance in the brain. Men suffering from depression are thought to have lower levels of some of the chemical messengers in the brain, called neurotransmitters. The three neurotransmitters believed to be involved in depression are serotonin, dopaine and noradrenaline. It is thought that, when levels of serotonin or the other brain chemicals drop, then symptoms of depression kick in. This fall in neurotransmitter levels can occur without there being any obvious reason. Just like the man who eats a healthy diet can still have high cholesterol, the man without any obvious underlying cause can develop symptoms of depression.
However, stressful life events such as losing your job, relationship difficulties or illness can also trigger depression.
Depression Part 1
Depression is common among Irish men and is often undiagnosed. Men tend to bottle up feelings, suppress and internalise emotions, and suffer stoically in silence. The natural resistance of the Irish male to seek help cialis pills Australia is compounded further by his general reluctance to discuss mental health issues. Some men still perceive depression to be a stigma, implying weakness or inadequacy. Nothing, however, could be further from the truth.
Unlike women, men are usually unable to articulate their feelings through their support networks or friends. Yet it is only through education and by increasing awareness of the symptoms, causes of and treatments for depression that we can help to bridge the gap that currently exists in Irish society for Irish men. Undiagnosed and untreated depression in severe forms can increase the risk of suicide, which is tragically all too common amongst Irish men, particularly young men.
Check out the self-assessment test for depression at the end of this chapter and see how you fare out. If you think you may be suffering from symptoms of depression, don’t suffer in silence. Your family doctor is there to help and support you.
Some Facts
- One in every four Irish men will develop depression at some time in their lives.
- Suicide is at least four times more common in men than women.
- The majority of suicides can be traced back to depression.
- Suicide is the biggest killer of young men aged 15-24.
Types of Depression
Depression is a medical condition caused by a chemical imbalance in the brain, usually a deficiency of serotonin (the happy hormone). This can occur as a reaction to a major, often traumatic, life event or to chronic stress. This type of depression is known as reactive depression.
I have often heard it said, ‘sure he has nothing to be depressed about.’ But sometimes depression can occur without there being any underlying reason and this is known as endogenous depression. This can affect anyone, irrespective of upbringing, address or bank balance.
Bipolar disorder, which used to be called ‘manic depression’, is a much less common condition. This is where episodes of elation or mania alternate with bouts of depression.
What Are the Symptoms of Depression?
Temporary feelings of sadness or depression are part of the normal ups and downs of everyday life. Clinical depression is more than that. Some or all of the following symptoms may be present:
- A low mood every day or most days for at least two weeks
- Loss of enjoyment or interest in usual activities, particularly things you would normally enjoy, like hobbies
Depression and Erectile Dysfunction
Depression is now a recognised medical condition and one of the problems with it is that you may not be aware you’re suffering from Depression. I provide a checklist for Depression because this issue is a common source of ED. But, it is only as a very general checklist due to the complexity of the problem. Have a look at the these symptoms and see if you can relate to any of them over a period of at least several weeks:
– You wonder whether life is worth living;
– You have lost interest in things you were previously interested in;
– You lack enthusiasm for anything;
– You have to push yourself to do tasks or your daily routine;
– You can’t concentrate and find most things meaningless;
– You suffer physically from lack of sleep, get tired easily, have lost weight, have no energy;
– You suffer mentally and feel irritable, tense, anxious and feel gloomy.
you are looking for Viagra store? here it is! the best prices and selection!
These factors don’t all have to be present but a combination of them requires professional attention in order to address the Depression issue. At the end of the day if you’re truly, clinically depressed, then ED is a common consequence.
A recent Japanese study established a link between Depression and ED and poses an interesting question as to whether Depression itself can be treated by treating ED. It makes sense that overcoming ED will boost one’s confidence. (Source: LUTS: Lower Urinary Tract Symptoms, doi: 10.1111/j.l 757-5672.2011.00140.x).
Depression has been linked to serotonin levels produced by the body. We have briefly discussed how one’s reaction to a sex encounter through the autonomous nervous system can take the Parasympathetic or Sympathetic nervous paths. If you are suffering from any kind of serotonin imbalance, then the undesirable Parasympathetic path is more likely.
The good news is that if Depression is the source of your ED condition, then with effective treatment of Depression your ED will also be treated. Likewise, drugs can easily treat any serotonin imbalance. Please refer to your Doctor for a referral to a psychiatrist, or psychologist. A psychiatrist specialises in psychological aspects of medicine and a psychologist is not medically qualified but may be so as a clinical psychologist. Experience in sexual disorders is a plus. It is also common these days for Doctors to treat Depression themselves.
After clinical treatment HealthCare Mall of Depression you should still follow my Step by Step Therapy program to effectively treat your ED and to improve your sexual prowess because, as I have already explained, there is usually more than one inter linked source.